Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Abstract

PURPOSE We evaluated rapid androgen cycling in combination with docetaxel for men with progressive noncastrate prostate cancers. PATIENTS AND METHODS Noncastrate patients with <or= 6 months of hormone therapy were eligible. Cohort 1 (62 patients) received six 28-day cycles of docetaxel (75 mg/m(2)), leuprolide, and 7 days of topical testosterone. Cohort 2… (More)
DOI: 10.1200/JCO.2007.15.1928

Topics

Cite this paper

@article{Rathkopf2008PhaseIT, title={Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.}, author={Dana E. Rathkopf and Michael Anthony Carducci and Michael J. Morris and Susan F. Slovin and Mario A. Eisenberger and Roberto Pili and Samuel Ray Denmeade and Moshe Kelsen and Tracy Curley and Melinda Halter and Connie Collins and Martin Q. Fleisher and Glenn Heller and Sharyn D. Baker and Howard I. Scher}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2008}, volume={26 18}, pages={2959-65} }